AIF Cancer Research Results

AIF, Apoptosis-Inducing Factor: Click to Expand ⟱
Source:
Type:
AIF is a mitochondrial oxidoreductase that contributes to cell death programmes and participates in the assembly of the respiratory chain.
Nuclear translocation of AIF occurs during cell death and has been associated with human disorders. Expression Levels:
AIF is often found to be overexpressed in several types of cancers, including breast, lung, and colorectal cancers.
The expression of AIF can vary significantly between different tumor types and even among patients with the same type of cancer.
Survival Rates:
High levels of AIF expression have been associated with poor prognosis in certain cancers, indicating a potential role in tumor aggressiveness and metastasis.
Conversely, low AIF expression may correlate with better survival outcomes in some contexts.
Overexpression: In many cancers, AIF is overexpressed, which is often associated with poor prognosis, increased tumor aggressiveness, and resistance to therapy.
Mye, Myeloma: Click to Expand ⟱

Myeloma - Plasma Cell Malignancy

Alternative Names: Multiple myeloma, plasma cell myeloma

Type: Hematologic malignancy / plasma cell cancer

Origin: Malignant transformation and clonal expansion of antibody-producing plasma cells, usually within the bone marrow.

Function/Characteristics: Myeloma cells produce monoclonal immunoglobulins or light chains and can disrupt normal bone marrow function, bone remodeling, renal function, and immune regulation.

Common Features: Bone marrow infiltration, osteolytic bone lesions, anemia, elevated monoclonal protein, renal dysfunction, hypercalcemia, and impaired normal antibody production.

Common Markers: CD38, CD138, BCMA (TNFRSF17), SLAMF7, and monoclonal immunoglobulin/light-chain expression.
Scientific Papers found: Click to Expand⟱
7437- CYN,    Cynaropicrin disrupts tubulin and c-Myc-related signaling and induces parthanatos-type cell death in multiple myeloma
- in-vitro, Mye, AMO1 - in-vivo, Mye, NA - in-vitro, Mye, KMS11 - in-vitro, Mye, JJN3 - in-vitro, Mye, MolP8 - in-vitro, Mye, L363 - in-vitro, Mye, H929
tumCV↓, cMyc↓, STAT3↓, Akt↓, ERK↓, TumCCA↑, DNAdam↑, PARP1↑, AIF↑, TumCG↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Mitochondria & Bioenergetics(tgid=3) ⓘ

AIF↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

cMyc↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

tumCV↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 1,   PARP1↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ERK↓, 1,   STAT3↓, 1,   TumCG↓, 1,  
Total Targets: 10

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: AIF, Apoptosis-Inducing Factor
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:92  Cells:%  prod#:%  Target#:520  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page